Cambridge Antibody Tech Group PLC
18 May 2006
Page 1 of 1
FOR IMMEDIATE RELEASE
Thursday 18th May 2006
For further information contact:
Cambridge Antibody Technology Hogarth (Europe)
Tel: +44 (0) 1223 471 471 Tel: +44 (0) 20 7357 9477
Peter Chambre, Chief Executive Officer Melanie Toyne-Sewell
John Aston, Chief Financial Officer Andrew Jaques
Rowena Gardner, Director of Corporate
Communications
BMC Communications/The Trout Group(USA)
Tel: 001 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext 15 (investors)
NOTIFICATION OF RESULTS
Cambridge, UK... Cambridge Antibody Technology Group plc ("CAT") (LSE: CAT;
NASDAQ: CATG) will be announcing its interim results at 7am BST on Monday 22 May
2006. Following the recent announcement of the recommended cash offer by
AstraZeneca International plc for CAT, the Company will be issuing a shortened
interims statement reflecting the Company's present position, but will not be
holding a group meeting or conference call for analysts on the day.
- ENDS -
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.